Herzinger T et al. |
Sphingosine-1-phosphate signaling and the skin. |
2007 |
Am J Clin Dermatol |
pmid:18039015
|
Rosini JM et al. |
Delayed cardiac dysrhythmias after fingolimod administration. |
2015 |
Am J Emerg Med |
pmid:25669873
|
Thomas RH and Wakefield RA |
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. |
2015 |
Am J Health Syst Pharm |
pmid:25511835
|
Fox EJ |
Emerging oral agents for multiple sclerosis. |
2010 |
Am J Manag Care |
pmid:20873946
|
Weinstock-Guttman B |
An update on new and emerging therapies for relapsing-remitting multiple sclerosis. |
2013 |
Am J Manag Care |
pmid:24494635
|
Campbell JD et al. |
Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. |
2013 |
Am J Manag Care |
pmid:23725360
|
Camm J et al. |
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. |
2014 |
Am. Heart J. |
pmid:25440790
|
Deutschman DH et al. |
Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. |
2003 |
Am. Heart J. |
pmid:12851609
|
Zhang Q et al. |
Berberine Preconditioning Protects Neurons Against Ischemia via Sphingosine-1-Phosphate and Hypoxia-Inducible Factor-1[Formula: see text]. |
2016 |
Am. J. Chin. Med. |
pmid:27430910
|
Lev M |
Sphingolipid biosynthesis and vitamin K metabolism in Bacteroides melaninogenicus. |
1979 |
Am. J. Clin. Nutr. |
pmid:32765
|